ELDERPHARM

Members of the Exchange are hereby notified that in terms of Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009, Section 21A of the Securities Contract (Regulations) Act, 1956, Rule 21(2) b of Securities Contract (Regulations) Rules, 1957, it has been decided to delist (withdraw the admission to dealings in) equity shares of the Elder Pharmaceuticals Limited w.e.f. May 30, 2018.

Members of the Exchange are hereby informed that the Exchange on February 28, 2018 has issued public notice in the newspaper for�� proposed compulsory delisting of equity shares of the company, in term of Regulation 22 (3) of SEBI (Delisting of Equity shares) Regulation, 2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/common/CorporateAnnouncements).

The Exchange has sought clarification from the Company with respect to news item captioned "Elder Pharma files for Insolvency". In this regard, Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company is aware of any information that has not been announced to

The Exchange has sought clarification from Elder Pharmaceuticals Limited with respect to recent news item captioned ''Elder Pharma, embroiled in bribery case, is among the biggest defaulters and the Ministry is doing nothing''. In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this a

Elder Pharmaceuticals Limited has informed the Exchange regarding the Outcome of Board Meeting of the Company held on February 03, 2016.

Elder Pharmaceuticals Limited has informed the Exchange that the Promoter have appointed Non-Executive Independent Directors i.e. Mr. Ravani Mohammed Abdul Khader and Mr. Kader Mohammed Davawala as Additional Directors w.e.f. January 25, 2016. Further Dr. (Mrs.) Babita Bhatia was appointed as Additional Director on July 15, 2015 who shall hold office up to the date of the next Annual General Meeting or the last date on which the Annual General Meeting should have been held, whichever is earlier. The last date of the Annual General Meeting was December 31, 2015 and the same is delayed. Therefor

Members of the Exchange are hereby informed that trading in Equity shares of Elder Pharmaceuticals Limited shall be transferred to BZ series with effect from December 28, 2015 due to non-compliances of the Clause 41 of the Listing Agreement for two consecutive quarters i.e. June 2015 and September 2015.

Elder Pharmaceuticals Limited has informed the Exchange that Dr. Sailendra Narain as Non -Executive Independent Director has tendered his resignation as Director of the company with effect from October 20, 2015.Further Company would like to thanks to Dr. Sailendra Narain for the assistance and guidance provided by him during his tenure as Director of the company.Company is in process to find right candidate for appointment of Additional Director on the Board to comply with the requirement as per Companies Act, 2013 and corporate Governance norms under clause 49 of listing agreement.

Elder Pharmaceuticals Limited has informed the Exchange that Dr. Joginder Singh Juneja as Non -Executive Independent Director has tendered his resignation as Director of the company with effect from October 21, 2015.Further Company would like to thanks to Dr. Joginder Singh Juneja for the assistance and guidance provided by him during his tenure as Director of the company.Company is in process to find right candidate for appointment of Additional Director on the Board to comply with the requirement as per Companies Act, 2013 and corporate Governance norms under clause 49 of listing agreement.

Elder Pharmaceuticals Limited has informed the Exchange vide letter dated October 12, 2015 regarding Clarification on various reports in News Papers.

Elder Pharmaceuticals Limited has informed the Exchange that the Meeting of the Board held on September 28, 2015 regarding the sale of the step down overseas subsidiaries, the matter was discussed by the Board of the Company and it was deliberated that complying with the legal parameters, the proposal should be put forward before the Board of Elder Pharmaceuticals Ltd. by the Board of Elder International , FZCO - Dubai for further consideration and necessary approval.

The Exchange has sought clarification from Elder Pharmaceuticals Limited with respect to recent news item captioned Elder Pharma to sell assets to clear debt . The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Elder Pharmaceuticals Limited has submitted their response.

The Exchange has sought clarification from Elder Pharmaceuticals Limited, with respect to recent news item captioned "Elder Pharma to sell assets to clear debt". In this regard, the Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such negotiations were taking place and b) Whether you/company are aware of any information that has not been announced to the Exchanges which could explain the aforesaid movement in the trading. The response from the company is awaited.

Elder Pharmaceuticals Limited has informed the Exchange that Mr. Bimal Desai, Chief Financial Officer of the Company has resigned w.e.f. August 31, 2015.Management has accepted his resignation and he has been relived from the services of the Company.

Elder Pharmaceuticals Limited has informed the Exchange that the Board at its meeting held on July 15, 2015, has passed resolution for appointment of Dr. (Mrs.) Babita Bhatia as Additional Director (Woman Director) w.e.f . July 15, 2015 in compliance with the Companies Act , 2013 and the amendments made to Clause 49 of the Listing Agreement .

Significant price movement has been observed in Elder Pharmaceuticals Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. The Company has submitted its clarification.

Elder Pharmaceuticals Limited has informed the Exchange regarding clarification on news item captioned "Elder Pharma got Rs. 2000 Cr by liquidating assets?". The Company has clarified that "The article is completely false and misleading and maligns company reputation by alleging money laundering by the management. This article is grossly defamatory and calculated to lower the standing and image of Elder Pharmaceuticals Ltd in the market. The said Article is thoroughly defamatory and published with malafide intentions with a view to hamper any effort made by the Company to revive and pay. Elder

Elder Pharmaceuticals Limited has submitted to the exchange the standalone & consolidated financial results along with the Limited Review Report for the period ended 31-Mar-2015.

Elder Pharmaceuticals Limited has submitted to the Exchange a copy of Minutes of Annual General Meeting of the Company held on March 24, 2015.

Elder Pharmaceuticals Limited has informed the Exchange regarding the Voting Results (e-voting and Ballot) of the Annual General Meeting of the Company held on March 24, 2015.

Elder Pharmaceuticals Limited has informed the Exchange that Board Considered and approved the Financial year of the Company w.e.f. July 01, 2014 to June 30, 2015.

Elder Pharmaceuticals Limited has informed the Exchange regarding the Outcome of Annual General Meeting of the Company held on March 24, 2015.

Elder Pharmaceuticals Limited has informed the Exchange, vide letter dated March 11, 2015 regarding an announcement titled "Elder Pharmaceuticals Limited completes making statutory payments".

Elder Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at their meeting held on February 13, 2015 have decided to hold Annual General Meeting on March 24, 2015.

Elder Pharmaceuticals Limited has submitted to the exchange the standalone & consolidated financial results along with the Limited Review Report for the period ended 31-Dec-2014.

Price movement : Significant price movement has been observed in Elder Pharmaceuticals Limited.. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Elder Pharmaceuticals Limited has vide its letter inter-alia stated, "The Company is not aware about the reason for increase in price of share of the Company. The Company has neither proposed nor is contemplating any acquisition or merger or issue of fresh shares, or otherwise, that has led

Elder Pharmaceuticals Limited has informed the Exchange that Mr. Saleem Shervni, Non-Executive-Independent Director of the Company has tendered his resignation as Non-Executive-Independent Director Of the Company with effect from December 11, 2014.

Elder Pharmaceuticals Limited has informed the Exchange that the Company has been granted extension of time for holding Annual General Meeting upto March 30, 2015 (3 months) by Registrar of Companies, Maharashtra, Mumbai.

Elder Pharmaceuticals Limited has informed the Exchange that the Company is not holding its 31st Annual General Meeting on December 31, 2014 because Company has applied for the extension of time to Registrar of Companies for holding of Annual General Meeting up to March 31, 2015.

Elder Pharmaceuticals Limited has informed the Exchange that as per the Listing Agreement and Section 203 of the Companies Act 2013 read with the Companies (Appointment Remuneration of Managerial Personnel) Rules, 2014, Mr. Bimal Desai is been appointed as Chief Financial Officer (CFO) of the Company w.e.f. December 01, 2014.

Elder Pharmaceuticals Limited has informed the Exchange that Dr. Jayaram Subramanian Non-Executive Independent Director of the Company has tendered his resignation as Non-Executive Independent Director of the Company with effect from December 01, 2014.

Elder Pharmaceuticals Limited has informed the Exchange that Mrs. Urvashi Saxena, Non-Executive Independent Director has tendered her resignation as Director of the company with effect from November 28, 2OI4. Further Company would like to thanks to Mrs. Urvashi Saxena for the assistance and guidance provided by her during her tenure as Director of the company.

Elder Pharmaceuticals Limited has informed the Exchange that the Register of Members & Share Transfer Books of the Company will remain closed from December 24, 2014 to December 31, 2014 (both days inclusive) for the purpose of Annual General Meeting (AGM) of the Company to be held on December 31, 2014. (Revised Book Closure Dates)

Elder Pharmaceuticals Limited has submitted to the exchange the standalone & consolidated financial results along with the Limited Review Report for the period ended 30-Sep-2014.

Elder Pharmaceuticals Limited has informed the Exchange that the Register of Members & Share Transfer Books of the Company will remain closed from December 22, 2014 to December 29, 2014 (both days inclusive) for the purpose of Annual General Meeting (AGM) of the Company to be held on December 29, 2014.

Elder Pharmaceuticals Limited has informed the Exchange that at the meeting of the Board of Directors of the Company held on November 14, 2014: 1. The Board accepted the resignation of Mr. Farid R Gulmohamed, Additional Director of the Company w.e.f. November 14, 2014; 2. The Board accepted the resignation of Mr. Yusuf Karim Khan, Executive Director of the Company w.e.f. November 12, 2014; 3. The Board accepted the resignation of Mr. Suresh Pai, Chief Financial Officer of the Company who will be resigning w.e.f. November 30, 2014.

Elder Pharmaceuticals Limited has submitted to the exchange the standalone & consolidated financial results for the period ended 30-Jun-2014.

Elder Pharmaceuticals Limited has submitted to the Exchange outcome of Board Meeting held on August 21, 2014. 1) The Board appointed Dr. Anuj Saxena as Chief Operating Officer (COO) of the Company without Remuneration for a period from August 21, 2014 to August 20, 2019.

Elder Pharmaceuticals Limited has informed the Exchange that Mr Michael Bastian, Non-Executive Directors has tendered his resignation as Director of the company with effect from August 09, 2014. Further Company would like to thanks to Mr Michael Bastian for the assistance and guidance provided by him during his tenure as Director of the Company.

Elder Pharmaceuticals Limited has informed the Exchange that Dr J.S. Juneja, Non- executive- independent Director of the Company has tendered his resignation as Non- Executive Chairman of the Company with effect from August 01, 2014. However he will continue to serve on the Board as Non-executive independent Director of the Company.

Elder Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on July 04, 2014.

Elder Pharmaceuticals Limited has informed the Exchange that Dr. Raghavachari Srinivasan, Director of the Company has resigned from the Board of the Company w.e.f. June 05, 2014.

Elder Pharmaceuticals Limited has informed the Exchange vide letter dated June 29, 2014 regarding "Elder Pharmaceuticals limited completes the sale of domestic branded formulations business with Torrent Pharmaceuticals limited".

Elder Pharmaceuticals Limited has informed the Exchange regarding "News reports in various media attributed to Press Trust Of India (PTI)".

Elder Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on May 15, 2014 has approved the following : (1). Resignation of Mr. James McEuen as Director of the Company.(2). Appointment of Mr. Vijendra Jain as Company Secretary & Compliance Officer of the Company in place of Mr. S.P. Date who has retired.

Elder Pharmaceuticals Limited has submitted to the exchange the standalone & consolidated financial results for the period ended 31-Mar-2014.

Sneh J Saxena has submitted to the Exchange, vide letter dated April 16, 2014 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Akshaya Holdings Pvt ltd has submitted to the Exchange vide letter dated April 07, 2014 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Akshaya Holdings pvt ltd has submitted to the Exchange vide letter dated April 04, 2014 a copy of Disclosure in terms of Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Nita Saxena has submitted to the Exchange vide letter dated April 02 , 2014 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.